In 2024, the U.S. healthcare system saw significant shifts in medicine use, patient access, and spending - driven by the growing impact of GLP-1s, targeted oncology therapies, immunologics, and changing vaccination trends.

Join the IQVIA Institute for a data-rich, forward-looking discussion on how clinical innovation is reshaping the treatment landscape - and what this means for affordability, equity, and access in the years ahead.

Who Should Attend:

This session is designed for senior leaders and decision-makers across:

• Pharmaceutical and biotech companies (Market Access, Commercial Strategy, Medical Affairs, HEOR)
• Payers and managed care organizations
• Health systems and integrated delivery networks
• Health policy and public sector agencies
• Investment and advisory firms focused on biopharma innovation

What You’ll Learn:

• Key drivers of medicine use and spending in 2024 across GLP-1s, oncology, immunology, and vaccines
• How novel therapies are reshaping patient access—and the barriers that remain
• What’s ahead for U.S. healthcare spending with the rise of biosimilars, generics, and continued GLP-1 adoption
• Trends in health equity and utilization across geographies and populations
• Strategic implications for payers, providers, and innovators navigating this evolving landscape

Don’t miss this opportunity to gain timely insight into the future of U.S. medicine use and access.

Speakers:

Stacie Dusetzina, Ph.D.
Professor, Health Policy Ingram Professor of Cancer Research, Vanderbilt University Medical Center

John Michael O'Brien, PharmD
President and CEO, National Pharmaceutical Council

Amanda Frost, Ph.D.
Vice President, Research, Pharmaceutical Care Management Association (PCMA)

Luke Greenwalt, MBA
VP, Thought Leadership and Innovation, U.S., IQVIA